Orthocell Posts Record U.S. Monthly Sales for Nerve Wrap Device
Orthocell's Remplir collagen nerve wrap hit a new U.S. sales peak in October 2026, signaling growing market traction for the FDA-cleared device.
Australian medical device maker Orthocell Ltd recorded its strongest month of U.S. sales for its Remplir collagen nerve wrap since the product launched, with 92 units sold in October 2026, according to the company.
Remplir is an FDA-cleared collagen nerve wrap engineered to support the repair and protection of peripheral nerves. The device is designed and manufactured in Australia, and Orthocell has been positioning it as a category leader in key international markets as adoption accelerates.
Read more Bahrain Grants Golden Licenses for $3.89B in New Projects at Gulf Summit →
The October milestone marks a meaningful inflection point for the company's commercial strategy in the United States, one of the most competitive and lucrative medical device markets globally. Sustained monthly growth in unit sales typically signals deepening relationships with surgical centers and specialist physicians, though the company did not disclose revenue figures alongside the unit count.
Peripheral nerve repair is a specialized surgical segment with limited proven options, and FDA-cleared products that demonstrate consistent clinical utility tend to gain referral momentum over time. Orthocell's ability to reach a new sales high in a single month suggests its U.S. commercial infrastructure is gaining efficiency, even as the broader medtech sector faces pricing and reimbursement pressures.
Continue reading at All Financial Services & Investing.
